Inovio's Zika vaccine induces immune responses in preclinical trial
The preclinical testing of Inovio Pharmaceuticals' synthetic DNA vaccine for the Zika virus induced durable immune responses. Inovio is developing its Zika vaccine with GeneOne Life Sciences and academic collaborators.In the pre-clinical study, Inovio's SynCon vaccine technology was used to synthetically generate DNA vaccine constructs targeting several Zika virus antigens.
Click on this link for more information.
